Analyst Price Targets — MRNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 28, 2026 11:19 am | John Eade | Argus Research | $180.00 | $142.77 | StreetInsider | Argus Upgrades Moderna (MRNA) to Buy |
| August 24, 2026 10:17 am | Eliana Merle | Barclays | $125.00 | $145.13 | TheFly | Moderna price target raised to $125 from $48 at Barclays |
| August 20, 2026 10:44 am | Michael Yee | UBS | $150.00 | $174.38 | TheFly | Moderna price target raised to $150 from $50 at UBS |
| August 19, 2026 6:00 pm | — | Goldman Sachs | $120.00 | $174.38 | TheFly | Moderna price target raised to $120 from $67 at Goldman Sachs |
| August 19, 2026 3:13 pm | Luca Issi | RBC Capital | $130.00 | $151.30 | TheFly | Moderna price target raised to $130 from $45 at RBC Capital |
| August 19, 2026 1:34 pm | Leah Rush Cann | Loop Capital Markets | $135.00 | $139.12 | StreetInsider | Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA) Following Positive Intismeran Data |
| August 19, 2026 12:54 pm | Michael Baker | D.A. Davidson | $245.00 | $138.21 | StreetInsider | DA Davidson Reiterates Neutral Rating on Lowe's (LOW) as Guidance Lowered |
| July 21, 2026 9:51 am | — | Goldman Sachs | $67.00 | $59.49 | TheFly | Moderna price target raised to $67 from $49 at Goldman Sachs |
| July 20, 2026 9:34 am | Alexandria Hammond | Wolfe Research | $25.00 | $61.82 | StreetInsider | Moderna (MRNA) PT Raised to $25 at Wolfe Research |
| July 8, 2026 11:39 am | — | Morgan Stanley | $39.00 | $79.77 | TheFly | Moderna price target raised to $39 from $33 at Morgan Stanley |
Latest News for MRNA
On Sept. 1, 2026, rising crude and Treasury yields pressured equities across nearly every sector, with tech stocks bearing the brunt of the selloff.
Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the stock is climbing anyway.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m.
Moderna and Merck recently announced positive results from a late-stage clinical study of their melanoma treatment. In recent years, Moderna has broadened its reach beyond its first product: the coronavirus vaccine.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MRNA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.